101
|
Rohrwasser A, Ishigami T, Gociman B, Lantelme P, Morgan T, Cheng T, Hillas E, Zhang S, Ward K, Bloch-Faure M, Meneton P, Lalouel JM. Renin and kallikrein in connecting tubule of mouse. Kidney Int 2004; 64:2155-62. [PMID: 14633138 DOI: 10.1046/j.1523-1755.2003.00302.x] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
BACKGROUND The observation of renin expression in connecting tubule, a segment that also expresses tissue kallikrein (KLK-1), raises two questions. Are the genes expressed in the same or in different cells of connecting tubule? Does this topography support the hypothesis that KLK-1 activates prorenin or is it more likely that it affords coordinated gene regulation? METHODS Renin and KLK-1 were examined by immunostaining and in situ hybridization. Renin activation by KLK-1 was investigated in vitro. In vivo, excretion of prorenin and active renin was compared in mice homozygous for targeted inactivation of KLK-1 (TK(-/-)) and normal littermates (TK(+/+)). RESULTS Using in situ immunostaining for renin and in situ hybridization for KLK-1 mRNA, we found that connecting tubule cells expressing renin also expressed KLK-1. We confirmed in vitro activation of prorenin by KLK-1, but found no difference in the ratio of active renin to prorenin in urine of TK(-/-) and TK(+/+) animals. Compared to TK(+/+) controls, TK(-/-) mice exhibited significantly lower 24-hour excretion of prorenin (5.05 +/- 1.16 mg Ang I/hour vs. 9.39 +/- 1.96 mg Ang I/hour, P < 0.05) and active renin (1.98 +/- 0.25 mg Ang I/hour vs. 3.58 +/- 0.39 mg Ang I/hour, P < 0.05), with no difference in either urine volumes or plasma renin concentrations. CONCLUSION Direct interaction between renin and KLK-1, not ruled out in vitro, is not supported in vivo. By contrast, lower excretion of active renin and prorenin in TK(-/-) compared to TK(+/+) suggest coordinated regulation of the two proteins in their participation to collecting duct function.
Collapse
Affiliation(s)
- Andreas Rohrwasser
- Department of Human Genetics, University of Utah, Health Sciences Center, Salt Lake City, Utah 84112, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
102
|
Bergaya S, Hilgers RHP, Meneton P, Dong Y, Bloch-Faure M, Inagami T, Alhenc-Gelas F, Lévy BI, Boulanger CM. Flow-Dependent Dilation Mediated by Endogenous Kinins Requires Angiotensin AT2Receptors. Circ Res 2004; 94:1623-9. [PMID: 15131008 DOI: 10.1161/01.res.0000131497.73744.1a] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The vascular kallikrein-kinin system contributes to about one third of flow-dependent dilation in mice carotid arteries, by activating bradykinin B2 receptors coupled to endothelial nitric oxide (NO) release. Because the bradykinin/NO pathway may mediate some of the effects of angiotensin II AT2 receptors, we examined the possible contribution of AT2 receptors to the kinin-dependent response to flow. Changes in outer diameter after increases in flow rate were evaluated in perfused arteries from wild-type animals (TK+/+) and in tissue kallikrein-deficient mice (TK-/-) in which the presence of AT2 receptor expression was verified. Saralasin, a nonselective angiotensin II receptor antagonist, impaired significantly flow-induced dilation in TK+/+, whereas it had no effect in TK-/- mice. In both groups, blockade of AT1 receptors with losartan or candesartan did not affect the response to flow. Inhibition of AT2 receptors with PD123319 reduced significantly flow-induced dilation in TK+/+ mice, but had no significant effect in TK-/- mice. Combining PD123319 with the bradykinin B2 receptor antagonist HOE-140 had no additional effect to AT2 receptor blockade alone in TK+/+ arteries. Flow-dependent-dilation was also impaired in AT2 receptor deficient mice (AT2-/-) when compared with wild-type littermates. Furthermore, HOE-140 significantly reduced the response to flow in the AT2+/+, but not in AT2-/- mice. In conclusion, this study demonstrates that the presence of functional AT2 receptors is necessary to observe the contribution of the vascular kinin-kallikrein system to flow-dependent dilation.
Collapse
MESH Headings
- 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid/pharmacology
- Acetylcholine/pharmacology
- Angiotensin II Type 1 Receptor Blockers/pharmacology
- Angiotensin II Type 2 Receptor Blockers
- Animals
- Benzimidazoles/pharmacology
- Biphenyl Compounds
- Bradykinin/analogs & derivatives
- Bradykinin/pharmacology
- Bradykinin B2 Receptor Antagonists
- Carotid Arteries/drug effects
- Carotid Arteries/physiology
- Carotid Arteries/ultrastructure
- Hemorheology
- Imidazoles/pharmacology
- Losartan/pharmacology
- Male
- Mesenteric Arteries/drug effects
- Mesenteric Arteries/physiology
- Mesenteric Arteries/ultrastructure
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Phenylephrine/pharmacology
- Pyridines/pharmacology
- Receptor, Angiotensin, Type 2/deficiency
- Receptor, Angiotensin, Type 2/genetics
- Receptor, Angiotensin, Type 2/physiology
- Receptor, Bradykinin B2/physiology
- Tetrazoles/pharmacology
- Tissue Kallikreins/deficiency
- Tissue Kallikreins/genetics
- Tissue Kallikreins/physiology
- Vasodilation/drug effects
- Vasodilation/physiology
- Vasodilator Agents/pharmacology
Collapse
Affiliation(s)
- Sonia Bergaya
- Institut National de la Santé et de la Recherche Médicale, Unit 541, Hôpital Lariboisière, Paris, France
| | | | | | | | | | | | | | | | | |
Collapse
|
103
|
Cardoso CC, Garrett T, Cayla C, Meneton P, Pesquero JB, Bader M. Structure and expression of two kininogen genes in mice. Biol Chem 2004; 385:295-301. [PMID: 15134344 DOI: 10.1515/bc.2004.025] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
AbstractKininogens serve dual functions by forming a scaffold for the assembly of the protein complex initiating the surface-activated blood coagulation cascade and as precursors for the kinin hormones. While rats have three kininogen genes, for mice, cattle, and humans only one gene has been described. Here, we present sequence and expression data of a second mouse kininogen gene. The two genes, kininogen-I and kininogen-II, are located in close proximity on chromosome 16 in a headtohead arrangement. In liver and kidney, both genes are expressed and for each gene three alternative splice variants are synthesized. Two of them are the expected high and low molecular weight isoforms known from all mammalian kininogens. However, for both genes also a third, hitherto unknown splice variant was detected which lacks part of the high molecular weight mRNA due to splicing from the low molecular weight donor site to alternative splice acceptor sites in exon 10. The physiological functions of the six kininogen isoforms predicted by these findings need to be determined.
Collapse
Affiliation(s)
- Cibele C Cardoso
- Max-Delbrück-Center for Molecular Medicine, D-13092 Berlin-Buch, Germany
| | | | | | | | | | | |
Collapse
|
104
|
Bergaya S, Matrougui K, Meneton P, Henrion D, Boulanger CM. Role of tissue kallikrein in response to flow in mouse resistance arteries. J Hypertens 2004; 22:745-50. [PMID: 15126916 DOI: 10.1097/00004872-200404000-00017] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND Tissue kallikrein, an essential enzyme in the formation of vascular kinins, contributes to flow-dependent dilatation (FDD) in large arteries. We hypothesized that the vascular kinin-kallikrein system may be involved in shear stress signalling in small resistance arteries, which have a key role in the systemic regulation of blood pressure. OBJECTIVE To investigate the role of the vascular kallikrein-kinin system in mesenteric resistance arteries of mice during acute changes in blood flow. DESIGN Arteries from wild-type mice (TK) and mice lacking tissue kallikrein (TK) were mounted in an arteriograph for the recording of changes in outer diameter during step increases in flow rate. RESULTS Responses to phenylephrine, acetylcholine or sodium nitroprusside were not different between the two strains. FDD was significantly reduced in arteries of TK mice compared with that in mesenteric arteries of TK mice exposed to phenylephrine (P = 0.04). FDD was no longer different between TK and TK mice when experiments were performed in the presence of the nitric oxide synthase (NOS) inhibitor N-nitro-l-arginine methyl ester (l-NAME; P = 0.26), l-NAME plus diclofenac (P = 0.73), or l-NAME plus diclofenac plus potassium chloride (P = 0.31), indicating that inactivation of tissue kallikrein preferentially affects the contribution of nitric oxide to flow response. However, expression of endothelial NOS was comparable between TK and TK mesenteric arteries. Finally, the bradykinin B2 receptor antagonist, HOE-140, significantly decreased FDD in TK but not in TK arteries (P = 0.03 and P = 0.82, respectively). CONCLUSION These results demonstrate the specific role of the tissue kallikrein in flow-induced dilatation, which is mediated by nitric oxide and bradykinin B2 receptor activation in resistance arteries.
Collapse
Affiliation(s)
- Sonia Bergaya
- Institut National de la Santé et de la Recherche Médicale (INSERM), Unit 541, Hôpital Lariboisière and Inserm Unit 367, 17 rue du Fer à Moulin, Paris, France
| | | | | | | | | |
Collapse
|
105
|
Kang BY, Bae JS, Lee KO. Genetic analysis of kallikrein‐kinin system in the Korean hypertensives. ACTA ACUST UNITED AC 2004. [DOI: 10.1080/12265071.2004.9647732] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
106
|
Yano Y, Ozono R, Nakashima H, Oishi Y, Kambe M, Hosoi K, Oshima T. Immunohistochemical Distributions of the Tissue Kallikrein-Kinin System in Ischemic and Non-Ischemic Mouse Heart. J Cardiovasc Pharmacol 2003; 42 Suppl 1:S49-53. [PMID: 14871029 DOI: 10.1097/00005344-200312001-00012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Kinins have been shown to play a cardioprotective role during myocardial ischemia. However, the localization of each of the components of the kallikrein-kinin system in the heart has not been determined in a cell type-specific manner. Recently, mK1 has been identified as the major tissue kallikrein with the strongest bradykinin-forming activity among the products of the mouse tissue kallikrein gene superfamily. In the study presented here, we investigated the localizations of mK1, kininogen and bradykinin B2 receptors (B2Rs) in ischemic and non-ischemic left ventricles by immunohistochemistry. Kininogen, which contains bradykinin as a surface epitope, was detected by an anti-bradykinin antibody. Changes in the amounts of mK1 and B2R were evaluated by Western blot analysis. Myocardial ischemia was induced by ligation of the left anterior descending coronary artery for 60 min followed by reperfusion for 24 h. mK1 and B2Rs were most abundantly expressed in the vascular endothelium and, to a lesser extent, in fibroblasts. No immunohistochemical signal of these molecules was detected in myocytes. Kininogen was localized in the vascular endothelium and the smooth muscle layer. Myocardial ischemia, although it had no effect on the localization of these molecules, increased the amounts of mK1 and B2R. We have obtained immunohistochemical evidence that all components of the tissue kallikrein-kinin system are present in the mouse heart. The coronary artery is the major site of kallikrein-kinin activity both in ischemic and non-ischemic hearts.
Collapse
MESH Headings
- Animals
- Blotting, Western
- Bradykinin/biosynthesis
- Bradykinin/immunology
- Bradykinin/pharmacokinetics
- Coronary Vessels/enzymology
- Endothelium, Vascular/enzymology
- Epitopes/immunology
- Epitopes/metabolism
- Heart Ventricles/enzymology
- Heart Ventricles/immunology
- Heart Ventricles/ultrastructure
- Immunoenzyme Techniques
- Kallikrein-Kinin System/immunology
- Kininogen, High-Molecular-Weight/immunology
- Kininogen, High-Molecular-Weight/metabolism
- Kininogen, Low-Molecular-Weight/immunology
- Kininogen, Low-Molecular-Weight/metabolism
- Ligation
- Male
- Mice
- Mice, Inbred C57BL
- Myocardial Ischemia/enzymology
- Myocardial Ischemia/immunology
- Myocardial Ischemia/physiopathology
- Receptor, Bradykinin B2/drug effects
- Receptor, Bradykinin B2/immunology
- Receptor, Bradykinin B2/ultrastructure
- Reperfusion
- Time Factors
- Tissue Kallikreins/biosynthesis
- Tissue Kallikreins/genetics
- Tissue Kallikreins/metabolism
Collapse
Affiliation(s)
- Yoko Yano
- Department of Clinical Laboratory Medicine, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan
| | | | | | | | | | | | | |
Collapse
|
107
|
Bascands JL, Schanstra JP, Couture R, Girolami JP. Les récepteurs de la bradykinine : de nouveaux rôles physiopathologiques. Med Sci (Paris) 2003; 19:1093-100. [PMID: 14648480 DOI: 10.1051/medsci/200319111093] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
In addition to being a pro-inflammatory mediator, bradykinin is now recognized as a neuromediator and regulator of several vascular and renal functions. New breakthroughs point to unusual and atypical signalling pathways for a G-protein coupled receptor that could explain the anti-proliferative and anti-fibrogenic effects of bradykinin. The availability of transgenic and knock out animal models for bradykinin receptors or bradykinin-synthesizing or -catabolic enzymes confirms these cardiac and renal protective roles for this peptide system. Bradykinin receptors are involved in the therapeutic action of angiotensin-1 converting enzyme inhibitors that are used in the treatment of arterial hypertension, heart failure and diabetes. Nevertheless, recent evidence highlights dissimilar mechanisms in the regulation and function of these receptors between the central nervous system and peripheral tissues. Therefore, the development of more specific bradykinin receptor agonists or antagonists devoid of central actions seems to evolve as a new therapeutic approach.
Collapse
Affiliation(s)
- Jean-Loup Bascands
- Inserm U.388, Institut Louis Bugnard, CHU Rangueil, avenue Jean-Poulhas, 31403 Toulouse Cedex 4, France
| | | | | | | |
Collapse
|
108
|
Hilgers RHP, Bergaya S, Schiffers PMH, Meneton P, Boulanger CM, Henrion D, Lévy BI, De Mey JGR. Uterine artery structural and functional changes during pregnancy in tissue kallikrein-deficient mice. Arterioscler Thromb Vasc Biol 2003; 23:1826-32. [PMID: 12933530 DOI: 10.1161/01.atv.0000090672.07568.60] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Tissue kallikrein (TK) participates in acute flow-induced dilatation (FID) of large arteries. We investigated whether TK deficiency blunts FID and alters chronic flow-related arterial structural and functional changes in resistance-sized muscular arteries. METHODS AND RESULTS Vasomotor responses and structural parameters were determined in uterine arteries isolated from nonpregnant, 18- to 19-day pregnant, and 7-day postpartum TK-/- and TK+/+ littermate mice. In TK-/- mice, values of diameter, medial cross-sectional area (CSA), myogenic tone, and dilatation in response to acetylcholine were comparable to those values in TK+/+ mice, but FID (0 to 100 microL/min) was significantly reduced (55+/-4% versus 85+/-4% in TK+/+ mice). In both mouse strains, pregnancy resulted in significant increases in diameter and medial CSA and in the Nw-nitro-l-arginine methyl ester-sensitive component of FID. By 7 days after pregnancy, uterine arterial diameter and CSA values no longer differed from nonpregnant values, and FID was markedly reduced in TK-/- and TK+/+ mice. CONCLUSIONS These observations (1) confirm at the level of resistance arteries the key role of TK in FID and (2) indicate that TK deficiency does not compromise arterial remodeling and changes in the contribution of NO to FID during and after pregnancy.
Collapse
Affiliation(s)
- Rob H P Hilgers
- Department of Pharmacology and Toxicology, Cardiovascular Research Institute Maastricht, Universiteit Maastricht, Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
109
|
Schmaier AH. The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. Am J Physiol Regul Integr Comp Physiol 2003; 285:R1-13. [PMID: 12793984 DOI: 10.1152/ajpregu.00535.2002] [Citation(s) in RCA: 120] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Understanding the physiological role of the plasma kallikrein-kinin system (KKS) has been hampered by not knowing how the proteins of this proteolytic system, when assembled in the intravascular compartment, become activated under physiological conditions. Recent studies indicate that the enzyme prolylcarboxypeptidase, an ANG II inactivating enzyme, is a prekallikrein activator. The ability of prolylcarboxypeptidase to act in the KKS and the renin-angiotensin system (RAS) indicates a novel interaction between these two systems. This interaction, along with the roles of angiotensin converting enzyme, cross talk between bradykinin and angiotensin-(1-7) action, and the opposite effects of activation of the ANG II receptors 1 and 2 support a hypothesis that the plasma KKS counterbalances the RAS. This review examines the interaction and cross talk between these two protein systems. This analysis suggests that there is a multilayered interaction between these two systems that are important for a wide array of physiological functions.
Collapse
Affiliation(s)
- Alvin H Schmaier
- The Univ. of Michigan, 5301 MSRB III, 1150 West Medical Center Dr., Ann Arbor, MI 48109-0640, USA.
| |
Collapse
|
110
|
Skidgel RA, Alhenc-Gelas F, Campbell WB. Prologue: kinins and related systems. New life for old discoveries. Am J Physiol Heart Circ Physiol 2003; 284:H1886-91. [PMID: 12742820 DOI: 10.1152/ajpheart.00164.2003] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Affiliation(s)
- Randal A Skidgel
- Department of Pharmaocolgy, University of Illinois College of Medicine, Chicago 60612, USA
| | | | | |
Collapse
|
111
|
Xiao HD, Fuchs S, Cole JM, Disher KM, Sutliff RL, Bernstein KE. Role of bradykinin in angiotensin-converting enzyme knockout mice. Am J Physiol Heart Circ Physiol 2003; 284:H1969-77. [PMID: 12637363 DOI: 10.1152/ajpheart.00010.2003] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Angiotensin-converting enzyme (ACE) plays a central role in the renin-angiotensin system. Whereas ACE is responsible for the production of angiotensin II, it is also important in the elimination of bradykinin. Constitutively, the biological function of bradykinin is mediated through the bradykinin B(2) receptor. ACE knockout mice have a complicated phenotype including very low blood pressure. To investigate the role of bradykinin in the expression of the ACE knockout phenotype, we bred B(2) receptor knockout mice with ACE knockout mice, thus generating a line of mice deficient in both the B(2) receptor and ACE. Surprisingly, these mice did not differ from ACE knockout mice in blood pressure, urine concentrating ability, renal pathology, and hematocrit. Thus abnormalities of bradykinin accumulation do not play an important role in the ACE knockout phenotype. Rather, this phenotype appears due to the defective production of angiotensin II.
Collapse
Affiliation(s)
- Hong D Xiao
- Department of Pathology, Emory University, Atlanta, Georgia 30322, USA
| | | | | | | | | | | |
Collapse
|
112
|
Maestri R, Milia AF, Salis MB, Graiani G, Lagrasta C, Monica M, Corradi D, Emanueli C, Madeddu P. Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. Hypertension 2003; 41:1151-5. [PMID: 12654715 DOI: 10.1161/01.hyp.0000064180.55222.df] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Experimental and clinical evidence suggests kinin involvement in adaptive myocardial growth. Kinins are growth-inhibitory to cardiomyocytes. Knockout of kinin B2 receptor (B2R) signaling causes dilated and failing cardiomyopathy in 129/J mice, and a 9-bp deletion polymorphism of human B2R is associated with reduced receptor expression and exaggerated left ventricular growth response to physical stress. We reasoned that genetic background and aging may significantly influence the impact of B2R mutation on cardiac phenotype. The theory was challenged in C57BL/6 mice, a strain that naturally differs from the 129/J strain, carrying 1 instead of 2 renin genes. C57BL/6 B2R knockouts (B2R-KO) showed higher blood pressure and heart rate levels (P<0.05) compared with wild-type controls (WT) at all ages examined. At 12 months, left ventricular contractility and diastolic function were mildly altered (P<0.05) and histological and morphological analyses revealed ventricular hypertrophy and cardiomyocyte enlargement in B2R-KO (P<0.01). Reparative fibrosis was enhanced by 208% and capillary density reduced by 38% (P<0.01). Functional and structural alterations induced by B2R deletion in C57BL/6 mice were less severe than those reported previously in the 129/J strain. We conclude that interaction of B2R signaling with other genetic determinants influences aging-related changes in myocardial structure and function. These findings may help us understand the role of kinins in the development of cardiac failure.
Collapse
Affiliation(s)
- Roberta Maestri
- Experimental Medicine and Gene Therapy Unit, Istituto Nazionale Biotecnologie e Biosistemi, Osilo, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
113
|
Abstract
The renin-angiotensin system (RAS) is critically involved in cardiovascular and renal function and in disease conditions, and has been shown to be a far more complex system than initially thought. A recently discovered homologue of angiotensin-converting enzyme (ACE)--ACE2--appears to negatively regulate the RAS. ACE2 cleaves Ang I and Ang II into the inactive Ang 1-9 and Ang 1-7, respectively. ACE2 is highly expressed in kidney and heart and is especially confined to the endothelium. With quantitative trait locus (QTL) mapping, ACE2 was defined as a QTL on the X chromosome in rat models of hypertension. In these animal models, kidney ACE2 messenger RNA and protein expression were markedly reduced, making ACE2 a candidate gene for this QTL. Targeted disruption of ACE2 in mice failed to elicit hypertension, but resulted in severe impairment in myocardial contractility with increased angiotensin II levels. Genetic ablation of ACE in the ACE2 null mice rescued the cardiac phenotype. These genetic data show that ACE2 is an essential regulator of heart function in vivo. Basal renal morphology and function were not altered by the inactivation of ACE2. The novel role of ACE2 in hydrolyzing several other peptides-such as the apelin peptides, opioids, and kinin metabolites-raises the possibility that peptide systems other than angiotensin and its derivatives also may have an important role in regulating cardiovascular and renal function.
Collapse
Affiliation(s)
- Gavin Y Oudit
- Department of Medical Biophysics and Richard Lewar/Heart and Stroke Center of Excellence, University of Toronto, Toronto, Canada
| | | | | | | |
Collapse
|
114
|
Farag NH, Mahata M, Ziegler MG, O'Connor DT, Mills PJ. Hormone replacement therapy increases renal kallikrein excretion in healthy postmenopausal women. Life Sci 2003; 72:1279-88. [PMID: 12570928 DOI: 10.1016/s0024-3205(02)02380-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Hypertension and its related increase in cardiovascular morbidity in postmenopausal women is a major public health problem. The hypotensive property of urinary kallikrein has been described since 1909. Despite the controversy surrounding the effects of hormone replacement therapy on blood pressure regulation, its mechanisms remain incompletely understood, and no evidence has yet been provided for its effects on renal kallikrein excretion in postmenopausal women. In a double-blind, randomized study we examined the effects of hormone replacement therapy in the form of 2 mg 17-beta estradiol (ERT) or 2 mg 17-beta estradiol combined with continuous 5 mg medroxyprogesterone acetate (HRT) on urinary kallikrein excretion in postmenopausal women. Thirty-nine postmenopausal women collected their urine for 24 hours on two separate occasions 3 months apart. During the 3 month period women were randomized to placebo, ERT, or HRT. Urine samples were assayed for kallikrein activity, normalized to urine creatinine and expressed as mU/gm creatinine. Urinary kallikrein excretion increased significantly after 3 months in the ERT (p < 0.001) and HRT (p < 0.01) groups, and decreased non-significantly in the placebo group (p > 0.06). There were no significant blood pressure changes after 3 months of therapy. The findings demonstrate that hormone replacement therapy in the form of estrogen or estrogen combined with continuous medroxyprogesterone is effective in increasing urinary kallikrein excretion. Given that a decrease in kallikrein excretion may mark risk for development of hypertension, the findings of this study are of value in demonstrating a novel mechanism underlying cardioprotective properties of postmenopausal hormone replacement therapy in women without pre-existing coronary disease.
Collapse
Affiliation(s)
- Noha H Farag
- Department of Psychiatry, UCSD Medical Center, University of California, 200 West Arbor Drive, CTF-A, 415, San Diego, La Jolla, CA 92103-0804, USA.
| | | | | | | | | |
Collapse
|
115
|
Trabold F, Pons S, Hagege AA, Bloch-Faure M, Alhenc-Gelas F, Giudicelli JF, Richer-Giudicelli C, Meneton P. Cardiovascular phenotypes of kinin B2 receptor- and tissue kallikrein-deficient mice. Hypertension 2002; 40:90-5. [PMID: 12105144 DOI: 10.1161/01.hyp.0000021747.43346.95] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
To clarify the role of the kallikrein-kinin system in cardiovascular homeostasis, the systemic and regional hemodynamics of kinin B2 receptor-deficient (B2-/-) and tissue kallikrein-deficient (TK-/-) mice were compared with their wild-type (WT) littermates on a pure C57BL/6 genetic background. B2-/-, TK-/-, and WT adult mice were normotensive and displayed normal hemodynamic (left ventricular [LV] pressure, cardiac output, total peripheral resistance, dP/dt(max)) and echocardiographic (septum and LV posterior wall thickness, LV diameter, LV mass, and LV fractional shortening) parameters. However, heart rate was lower in B2-/- mice compared with TK-/- and WT mice. In addition, B2-/- mice, but not TK-/- mice, exhibited lower coronary and renal blood flows and greater corresponding vascular resistances than did WT mice, indicating a tonic physiological vasodilating effect of bradykinin in these vascular beds. However, maximal coronary vasodilatation capacity, estimated after dipyridamole infusion, was similar in the 3 groups of mice. B2-/- mice were significantly more sensitive than were TK-/- mice to the vasoconstrictor effects of angiotensin II and norepinephrine. Finally, renin mRNA levels were significantly greater in B2-/- mice and smaller in TK-/- mice compared with WT mice. Taken together, these results indicate that under basal conditions, the kinin B2 receptor is not an important determinant of blood pressure in mice but is involved in the control of regional vascular tone in the coronaries and the kidneys. The phenotypic differences observed between TK-/- and B2-/- mice could be underlain by tissue kallikrein kinin-independent effect and/or kinin B1 receptor activation.
Collapse
MESH Headings
- Angiotensin II/pharmacology
- Animals
- Blood Pressure/drug effects
- Blood Pressure/physiology
- Blotting, Northern
- Bradykinin/pharmacology
- Cardiac Output/drug effects
- Cardiac Output/physiology
- Cardiovascular Physiological Phenomena/drug effects
- Dose-Response Relationship, Drug
- Female
- Genotype
- Heart Ventricles/drug effects
- Hemodynamics/drug effects
- Homeostasis/genetics
- Kallikreins/deficiency
- Kallikreins/genetics
- Ketamine/pharmacology
- Kidney/metabolism
- Male
- Mice
- Mice, Inbred C57BL
- Mice, Mutant Strains
- Norepinephrine/pharmacology
- Phenotype
- RNA, Messenger/genetics
- RNA, Messenger/metabolism
- Receptor, Angiotensin, Type 1
- Receptor, Bradykinin B2
- Receptors, Angiotensin/genetics
- Receptors, Bradykinin/deficiency
- Receptors, Bradykinin/genetics
- Regional Blood Flow/drug effects
- Renin/genetics
- Ventricular Function
- Xylazine/pharmacology
Collapse
Affiliation(s)
- Fabien Trabold
- Département de Pharmacologie, Faculté de Médecine Paris-Sud, INSERM 00-01, Le Kremlin-Bicêtre, France
| | | | | | | | | | | | | | | |
Collapse
|
116
|
Vanhoutte PM. Endothelial AT(2)-receptors: chicken or egg? Br J Pharmacol 2002; 136:481-3. [PMID: 12055125 PMCID: PMC1573385 DOI: 10.1038/sj.bjp.0704763] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2002] [Accepted: 04/17/2002] [Indexed: 11/08/2022] Open
Affiliation(s)
- Paul M Vanhoutte
- Institut de Recherches Internationales Servier, 6 Place des Pléiades, 92415 Courbevoie, France.
| |
Collapse
|
117
|
Crozatier B, Badoual T, Boehm E, Ennezat PV, Guenoun T, Su J, Veksler V, Hittinger L, Ventura-Clapier R. Role of creatine kinase in cardiac excitation-contraction coupling: studies in creatine kinase-deficient mice. FASEB J 2002; 16:653-60. [PMID: 11978729 DOI: 10.1096/fj.01-0652com] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
To understand the role of creatine kinase (CK) in cardiac excitation-contraction coupling, CK-deficient mice (CK-/-) were studied in vitro and in vivo. In skinned fibers, the kinetics of caffeine-induced release of Ca2+ was markedly slowed in CK-/- mice with a partial restoration when glycolytic substrates were added. These abnormalities were almost compensated for at the cellular level: the responses of Ca2+ transient and cell shortening to an increased pacing rate from 1 Hz to 4 Hz were normal with a normal post-rest potentiation of shortening. However, the post-rest potentiation of the Ca2+ transient was absent and the cellular contractile response to isoprenaline was decreased in CK-/- mice. In vivo, echocardiographically determined cardiac function was normal at rest but the response to isoprenaline was blunted in CK-/- mice. Previously described compensatory pathways (glycolytic pathway and closer sarcoplasmic reticulum-mitochondria interactions) allow a quasi-normal SR function in isolated cells and a normal basal in vivo ventricular function, but are not sufficient to cope with a large and rapid increase in energy demand produced by beta-adrenergic stimulation. This shows the specific role of CK in excitation-contraction coupling in cardiac muscle that cannot be compensated for by other pathways.
Collapse
|
118
|
Slim R, Torremocha F, Moreau T, Pizard A, Hunt SC, Vuagnat A, Williams GH, Gauthier F, Jeunemaitre X, Alhenc-Gelas F. Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. J Am Soc Nephrol 2002; 13:968-976. [PMID: 11912256 DOI: 10.1681/asn.v134968] [Citation(s) in RCA: 64] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Kallikrein is synthesized in the distal tubules and produces kinins, which are involved in the regulation of vascular tone in the kidney. Urinary kallikrein activity has been reported to be partly inherited and to be reduced in essential hypertension. In a systematic search for molecular variants of the human kallikrein gene, nine single-nucleotide polymorphisms were identified. Five of those polymorphisms, including two nonsynonymous substitutions in exon 3, i.e., Arg53His (allelic frequency in Caucasian subjects, 0.03) and Gln121Glu (allelic frequency, 0.33), were studied in a normotensive group and two independent hypertensive groups for which 24-h urinary kallikrein activity had been measured. A significant decrease in urinary kallikrein activity was observed for the subjects who were heterozygous for the Arg53His polymorphism, compared with the other subjects. This finding was consistent in the two hypertensive groups and was observed with several kallikrein enzymatic assays. The Gln121Glu polymorphism and the other polymorphisms were not associated with changes in urinary kallikrein activity. None of the polymorphisms was associated with hypertension. Recombinant kallikrein variants were synthesized and enzymatically characterized, using native kininogen and kininogen-derived synthetic peptide substrates. No important effect was observed after Gln121 mutation, but there was a major decrease in enzyme activity when Arg53 was replaced by histidine. A model of kallikrein derived from crystallographic data suggested that Arg53 can affect substrate binding. The identification of a subset of subjects with genetically reduced kallikrein activity as a result of an amino acid mutation could facilitate analysis of the role of the kallikrein-kinin system in renal and vascular diseases.
Collapse
Affiliation(s)
- Rola Slim
- *INSERM U367, Paris VI-University, France; Department of Genetics, Georges Pompidou European Hospital and INSERM U36, Paris, France; INSERM-François Rabelais University U10, Tours, France; Howard Hughes Institute of Human Genetics, University of Utah, Salt Lake City, Utah; and Endocrine-Hypertension Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Florence Torremocha
- *INSERM U367, Paris VI-University, France; Department of Genetics, Georges Pompidou European Hospital and INSERM U36, Paris, France; INSERM-François Rabelais University U10, Tours, France; Howard Hughes Institute of Human Genetics, University of Utah, Salt Lake City, Utah; and Endocrine-Hypertension Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Thierry Moreau
- *INSERM U367, Paris VI-University, France; Department of Genetics, Georges Pompidou European Hospital and INSERM U36, Paris, France; INSERM-François Rabelais University U10, Tours, France; Howard Hughes Institute of Human Genetics, University of Utah, Salt Lake City, Utah; and Endocrine-Hypertension Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Anne Pizard
- *INSERM U367, Paris VI-University, France; Department of Genetics, Georges Pompidou European Hospital and INSERM U36, Paris, France; INSERM-François Rabelais University U10, Tours, France; Howard Hughes Institute of Human Genetics, University of Utah, Salt Lake City, Utah; and Endocrine-Hypertension Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Steven C Hunt
- *INSERM U367, Paris VI-University, France; Department of Genetics, Georges Pompidou European Hospital and INSERM U36, Paris, France; INSERM-François Rabelais University U10, Tours, France; Howard Hughes Institute of Human Genetics, University of Utah, Salt Lake City, Utah; and Endocrine-Hypertension Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Albert Vuagnat
- *INSERM U367, Paris VI-University, France; Department of Genetics, Georges Pompidou European Hospital and INSERM U36, Paris, France; INSERM-François Rabelais University U10, Tours, France; Howard Hughes Institute of Human Genetics, University of Utah, Salt Lake City, Utah; and Endocrine-Hypertension Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Gordon H Williams
- *INSERM U367, Paris VI-University, France; Department of Genetics, Georges Pompidou European Hospital and INSERM U36, Paris, France; INSERM-François Rabelais University U10, Tours, France; Howard Hughes Institute of Human Genetics, University of Utah, Salt Lake City, Utah; and Endocrine-Hypertension Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Francis Gauthier
- *INSERM U367, Paris VI-University, France; Department of Genetics, Georges Pompidou European Hospital and INSERM U36, Paris, France; INSERM-François Rabelais University U10, Tours, France; Howard Hughes Institute of Human Genetics, University of Utah, Salt Lake City, Utah; and Endocrine-Hypertension Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - Xavier Jeunemaitre
- *INSERM U367, Paris VI-University, France; Department of Genetics, Georges Pompidou European Hospital and INSERM U36, Paris, France; INSERM-François Rabelais University U10, Tours, France; Howard Hughes Institute of Human Genetics, University of Utah, Salt Lake City, Utah; and Endocrine-Hypertension Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| | - François Alhenc-Gelas
- *INSERM U367, Paris VI-University, France; Department of Genetics, Georges Pompidou European Hospital and INSERM U36, Paris, France; INSERM-François Rabelais University U10, Tours, France; Howard Hughes Institute of Human Genetics, University of Utah, Salt Lake City, Utah; and Endocrine-Hypertension Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
119
|
Abstract
1. Kinin peptides are implicated in many physiological and pathological processes, including the regulation of blood pressure and sodium homeostasis, inflammation and the cardioprotective effects of preconditioning. In humans, the plasma and tissue kallikrein-kinin systems (KKS) generate bradykinin and kallidin peptides, respectively. 2. We established methodology for the measurement of bradykinin and kallidin peptides and their metabolites in order to study the function of the plasma and tissue KKS in humans. 3. Bradykinin peptides were more abundant than kallidin peptides in blood and cardiac atrial tissue, whereas kallidin peptides were predominant in urine. The levels of kinin peptides in tissue were higher than in blood, confirming the primary tissue localization of the KKS. 4. Angiotensin-converting enzyme inhibition increased blood levels of bradykinin and kallidin peptides. 5. Blood levels of kallidin peptides were suppressed in patients with severe cardiac failure, indicating that the activity of the tissue KKS is suppressed in this condition. 6. Bradykinin peptide levels were increased in the urine of patients with interstitial cystitis, suggesting a role for these peptides in the pathogenesis and/or symptomatology of this condition. 7. Cardiopulmonary bypass, a model of activation of the contact system, activated both the plasma and tissue KKS. 8. Measurement of individual bradykinin and kallidin peptides and their metabolites gives important information about the operation of the plasma and tissue KKS and their role in physiology and disease states.
Collapse
Affiliation(s)
- D J Campbell
- St Vincent's Institute of Medical Research and The University of Melbourne Department of Medicine, Fitzroy, Victoria, Australia.
| |
Collapse
|
120
|
Richer C, Domergue V, Gervais M, Fornes P, Trabold F, Giudicelli JF. Coronary dilatation reserve in experimental hypertension and chronic heart failure: effects of blockade of the renin-angiotensin system. Clin Exp Pharmacol Physiol 2001; 28:997-1001. [PMID: 11903302 DOI: 10.1046/j.1440-1681.2001.03573.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
1. The aim of the present study was to investigate left and right ventricular (LV and RV, respectively) coronary vasodilatation reserve (CVR; fluorescent microsphere technique) in rats with hypertension (spontaneously hypertensive rats (SHR)) or congestive heart failure (CHF) and the effects of early and chronic renin-angiotensin system (RAS) blockade thereupon. 2. In adult SHR, both LV and RV CVR were impaired, especially in the non-hypertrophied RV, the main factor involved being coronary vascular remodelling. Blockade of the RAS normalized both LV and RV CVR, mainly through the prevention of hypertension and suppression of the resulting pericoronary fibrosis. 3. In postischaemic CHF rats, there was an early and severe degradation of LV and RV CVR that developed before any significant vascular remodelling and appeared to be linked to the deterioration of cardiac hypertrophy and haemodynamics. This degradation in CVR further worsened over the longer term due to late-developing pericoronary fibrosis and endothelial dysfunction. Blockade of the RAS had no early effects on LV and RV CVR, but improved RV CVR over the long term, mainly by limiting RV hypertrophy and by preventing the development of pericoronary fibrosis and coronary endothelial dysfunction. 4. In kallikrein-kinin system-deficient mice, CVR was not different from that of wild-type mice, suggesting that this system is not implicated in normal CVR regulation.
Collapse
Affiliation(s)
- C Richer
- Département de Pharmacologie et INSERM 00-01, Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France.
| | | | | | | | | | | |
Collapse
|
121
|
Huang W, Gallois Y, Bouby N, Bruneval P, Heudes D, Belair MF, Krege JH, Meneton P, Marre M, Smithies O, Alhenc-Gelas F. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci U S A 2001; 98:13330-4. [PMID: 11687636 PMCID: PMC60870 DOI: 10.1073/pnas.231476798] [Citation(s) in RCA: 111] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
Diabetic nephropathy is a major risk factor for end-stage renal disease and cardiovascular diseases and has a marked genetic component. A common variant (D allele) of the angiotensin I-converting enzyme (ACE) gene, determining higher enzyme levels, has been associated with diabetic nephropathy. To address causality underlying this association, we induced diabetes in mice having one, two, or three copies of the gene, normal blood pressure, and an enzyme level range (65-162% of wild type) comparable to that seen in humans. Twelve weeks later, the three-copy diabetic mice had increased blood pressures and overt proteinuria. Proteinuria was correlated to plasma ACE level in the three-copy diabetic mice. Thus, a modest genetic increase in ACE levels is sufficient to cause nephropathy in diabetic mice.
Collapse
Affiliation(s)
- W Huang
- Institut National de la Santé et de la Recherche Médicale, Unit 367, 17 Rue du Fer a Moulin, 75005 Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
122
|
Bergaya S, Meneton P, Bloch-Faure M, Mathieu E, Alhenc-Gelas F, Lévy BI, Boulanger CM. Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice. Circ Res 2001; 88:593-9. [PMID: 11282893 DOI: 10.1161/01.res.88.6.593] [Citation(s) in RCA: 86] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
- Flow-dependent dilation is a fundamental mechanism by which large arteries ensure appropriate blood supply to tissues. We investigated whether or not the vascular kallikrein-kinin system, especially tissue kallikrein (TK), contributes to flow-dependent dilation by comparing wild-type and TK-knockout mice in which the presence or absence of TK expression was verified. We examined in vitro changes in the outer diameter of perfused carotid arteries from TK(+/+) and TK(-/-) mice. In both groups, exogenous bradykinin caused a similar dilation that was abolished by the B(2) receptor antagonist HOE-140, as well as by the NO synthase inhibitor N:(omega)-nitro-L-arginine methyl ester. However, purified kininogen dilated only TK(+/+) arteries, demonstrating the essential role of TK in the vascular formation of kinins. In TK(+/+) arteries, increasing intraluminal flow caused a larger endothelium-dependent dilation than that seen in TK(-/-). In both strains the flow response was mediated by NO and by endothelium-derived hyperpolarizing factor, whereas in TK(-/-) vasoconstrictor prostanoids participated as well. HOE-140 impaired flow-dependent dilation in TK(+/+) arteries while showing no effect in TK(-/-). This compound reduced the flow response in TK(+/+) arteries to a level similar to that in TK(-/-). After NO synthase inhibition, HOE-140 no longer affected the response of TK(+/+). Impaired flow-dependent dilation was also observed in arteries from knockout mice lacking bradykinin B(2) receptors as compared with wild-type animals. This study demonstrates the active contribution of the vascular kallikrein-kinin system to one-third of the flow-dependent dilation response via activation of B(2) receptors coupled to endothelial NO release.
Collapse
Affiliation(s)
- S Bergaya
- Institut National de la Santé et de la Recherche Médicale, Unit 541 Hôpital Lariboisière, Paris, France
| | | | | | | | | | | | | |
Collapse
|